From Company Creation through Public Investing
The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases
